DT’s Q2 results clearly topped estimates as SBU and IBU grew a lot faster than expected, while MBU s...
Net sales and EBIT were slightly below consensus (LSEG) in Q2.
Redeye updates on Raketech ahead of Q2-results (due 14 August) where we expect continued uncertainty...
We expect positive group revenue growth in Q2 after a decline for the last four quarters on a y/y ba...
Solteq published preliminary Q2 figures, showing better profitability than we had estimated, while t...
Mangold uppdaterar sin syn på sensorteknikbolaget JonDeTech Sensors (JonDeTech) efter det andra kvar...
Redeye justerar estimat och sänker base case med anledning av den negativa rekommendationen från EMA...
Redeye notes a weak Q2 for Sedana Medical, with lower sales and higher costs than we expected.
The beginning of 2024 was tough, but the worst could be behind us.
Net sales was above our expectation in Q2 but order book was down by 21% on y/y basis.
Redeye leaves its initial take on Xbrane following this mornings news that Xbrane has regained the f...
Q2 2024 profit before loan losses came in at DKK 63m, DKK 7m (10%) below our estimate.
Q2e: 4.0m EEs, 58k SCs pre-announced, expect SEK 13m EBIT Cut sales by ~4%, EBIT by ~6% on lower EE ...
Redeye comments on the published order of SEK 31m for OTS™ Hip stemming from the distribution agreem...
Q2e: one eMELT-iD and two Freemelt ONE deliveries Sales of SEK 13.
Obducat publicerade den 26 juli 2024 bolagets delårsrapport för det andra kvartalet 2024, vilken vis...
Etteplan publishes its Q2/24 figures on 8th of August.
Redeye updates on EG7 following the weaker-than-expected Q2-results which looks to be related to a c...
Overall demand weakness, combined with customer-specific problems, led Scanfil to downgrade its 2024...
Servicebolaget Coor rapporterade ett andra kvartal som kom in något över Analysguidens prognos.
